Published on

Urology – Prostate Cancer: Epidemiology, Risk Factors, Genetics, Diagnosis, Staging, and Management

1. Definition and Clinical Overview

Prostate cancer (CaP) refers to malignant neoplasia arising within the prostate gland.

More than 95% of prostate cancers are adenocarcinomas, while other histological types are uncommon.

Prostate adenocarcinoma generally originates from glandular epithelial cells and most frequently develops in the peripheral zone.

Main Clinical Categories

  • Localized prostate cancer.
  • Locally advanced prostate cancer.
  • Regional lymph node-positive disease.
  • Metastatic hormone-sensitive prostate cancer.
  • Nonmetastatic castration-resistant prostate cancer.
  • Metastatic castration-resistant prostate cancer.

Clinical Importance

Prostate cancer demonstrates marked biological variability.

Some tumours progress slowly and may never cause symptoms, whereas others are aggressive and may metastasize early.

Key Principle: Prostate Cancer Management Must Be Individualized According To Tumour Risk, Clinical Stage, Life Expectancy, Comorbidities, And Patient Preferences.


2. Epidemiology

Incidence

Prostate cancer is among the most commonly diagnosed solid malignancies in men.

Historical United States Statistics, 2014

The source reports:

  • 233,000 new cases.
  • 29,480 deaths.

These are historical figures rather than current annual estimates.

PSA Screening Era

Widespread use of prostate-specific antigen testing caused a marked increase in reported prostate cancer incidence between:

1989 and 1992.

Clinical Explanation

PSA testing increased detection of cancers that previously may not have been diagnosed during life.

Historical Mortality Trends

The source describes a significant reduction in mortality after 1991.

This trend reflects multiple possible contributors, including:

  • Earlier diagnosis.
  • Improved treatment.
  • Changes in population risk and clinical management.

Historical Five-Year Relative Survival

Approximately:

100%.

Important Qualification

This estimate largely reflects the very favorable survival of patients diagnosed with localized or regional disease.

Patients with distant metastatic disease have substantially less favorable outcomes.

Historical Lifetime Risk

Approximately:

16.15%.

Important Qualification

Lifetime risk depends on population, age, screening practices, and other factors.


3. Population and Geographic Variation

The historical source reports particularly high incidence among African American men.

Historical Relative Incidence

Approximately:

Twice That Of White American Men.

The source also describes lower incidence in several Asian populations.

Historical Example

China:

1.9 Cases per 100,000 Men per Year.

Migration Studies

The source notes increased prostate cancer incidence among Asian men who migrate to the United States.

Clinical Interpretation

Geographic and population differences suggest contributions from:

  • Genetic susceptibility.
  • Environmental exposures.
  • Lifestyle.
  • Screening practices.
  • Healthcare access.

Important Qualification

The historical incidence figures should not be applied directly to modern populations. Ancestry-associated risk is not deterministic for an individual patient.


4. Risk Factors

Prostate cancer development involves genetic, hormonal, environmental, and age-related influences.

Main Risk Factors

  • Increasing age.
  • Family history.
  • Inherited cancer-predisposition variants.
  • African ancestry in population-based epidemiological studies.
  • Other environmental and biological factors.


5. Family History

Clinical Significance

Risk increases according to:

  1. Number of affected relatives.
  2. Degree of biological relationship.
  3. Age at diagnosis.
  4. Presence of associated hereditary cancers.

Particularly Important

A first-degree relative with prostate cancer.

Clinical Importance

A Strong Family History, Particularly Early-Onset Prostate Cancer In Close Relatives, Raises Concern For Inherited Susceptibility.


6. Inflammation and Infection

The historical source identifies possible associations with:

  • Prostatitis.
  • Sexually transmitted infections.
  • Chronic inflammation.

Proposed Mechanisms

  • Persistent epithelial injury.
  • Inflammatory mediators.
  • Oxidative stress.
  • Increased cellular turnover.

Important Qualification

Associations between prostatitis, infection, and prostate cancer have been inconsistent across studies.

Chronic prostatitis is not an established direct cause of prostate cancer in every affected patient.


7. Oxidative Stress

Proposed Mechanism

Oxidative injury may damage cellular DNA.

Relevant Biological Processes

  • Reactive oxygen species production.
  • DNA damage.
  • Cellular repair mechanisms.
  • Accumulation of mutations.

Clinical Importance

Some genes investigated in prostate cancer susceptibility participate in oxidative damage repair.


8. Dietary Factors

The historical source identifies a Western dietary pattern characterized by:

  • High meat consumption.
  • High dairy intake.
  • Increased saturated fat.

Other Historical Associations

  • Folate supplementation.
  • Dietary antioxidant status.

Important Qualification

Associations between individual foods or supplements and prostate cancer are not equivalent to proven causation.

There is no established dietary supplement that reliably prevents prostate cancer.


9. Androgens

Physiological Role

Androgens are essential for normal development and function of the prostate gland.

Principal Hormone

Testosterone.

Important Active Metabolite

Dihydrotestosterone (DHT).

Biological Effects

Androgen signaling influences:

  • Prostatic epithelial growth.
  • Glandular differentiation.
  • Cellular survival.
  • Prostate cancer progression.

Clinical Importance

Androgen Receptor Signaling Is Central To Prostate Cancer Biology And Forms The Basis Of Hormonal Treatment For Advanced Disease.


10. Androgen Receptor Genetics

The source describes variation in the CAG repeat sequence of the androgen receptor gene.

Historical Association

Shorter CAG repeat length was associated with increased prostate cancer susceptibility in some studies.

Important Qualification

The clinical value of androgen receptor CAG repeat testing remains limited and is not part of routine prostate cancer risk assessment.


11. Other Hormonal Factors

Estrogens

May influence prostate growth and cancer biology.

The historical source describes mixed effects.

Insulin-Like Growth Factor 1

IGF-1.

Investigated in relation to cancer cell proliferation and survival.

Vitamin D

The original chapter proposes a protective effect.

Important Qualification

A protective clinical effect of vitamin D supplementation against prostate cancer has not been established.

Vitamin D supplementation should not be prescribed specifically to prevent prostate cancer without another appropriate indication.


12. Genetics of Prostate Cancer

General Principles

Prostate cancer may be:

  • Sporadic.
  • Familial.
  • Associated with inherited pathogenic variants.

The multifocal and heterogeneous nature of prostate cancer complicates genetic research.


13. Historical HPC1 Gene Association

Location

Chromosome 1.

The source describes the hereditary prostate cancer susceptibility region HPC1.

Associated Gene

RNASEL.

Proposed Mechanism

Disruption of antiviral and cellular RNA-related pathways may contribute to susceptibility.

Important Qualification

Historical candidate-gene associations have not all proved sufficiently predictive for routine clinical testing.


14. Other Historical Candidate Genes

The original source lists:

  • TP53.
  • ELAC2/HPC2.
  • MSR1.
  • CHEK2.
  • BRCA2.
  • PON1.
  • OGG1.
  • MIC1.

Clinical Importance

These genes were investigated because of their roles in:

  • DNA repair.
  • Tumour suppression.
  • Oxidative stress responses.
  • Cellular regulation.


15. Contemporary Hereditary Prostate Cancer Genetics

Important established cancer-predisposition genes include:

  • BRCA2.
  • BRCA1.
  • ATM.
  • CHEK2.
  • HOXB13.
  • Mismatch-repair genes associated with Lynch syndrome.

Mismatch-Repair Genes

  • MLH1.
  • MSH2.
  • MSH6.
  • PMS2.

Clinical Importance

BRCA2 Pathogenic Variants Are Particularly Important Because They May Increase The Risk Of Aggressive Prostate Cancer And Can Influence Screening And Treatment.


16. Genetic Counseling and Testing

Potential Indications

  • Strong family history of prostate cancer.
  • Multiple hereditary cancer diagnoses in the family.
  • Known familial pathogenic variant.
  • Selected high-risk prostate cancers.
  • Metastatic prostate cancer.
  • Tumour findings suggesting hereditary DNA repair deficiency.

Clinical Importance

Germline testing may influence:

  • Family counseling.
  • Screening strategies.
  • Treatment planning.
  • Eligibility for targeted therapy.


17. Familial Versus Sporadic Disease

The original source reports that familial prostate cancer may follow a clinical course similar to sporadic disease.

Important Qualification

Disease behavior varies according to the underlying genetic alteration.

Some inherited pathogenic variants, particularly BRCA2, are associated with more aggressive disease.


18. Normal Prostate Anatomy and Function

Historical Adult Prostate Weight

Approximately:

20–25 g.

Secretory Function

The prostate contributes fluid to semen.

Historical Contribution

Approximately:

30% of Ejaculate Volume.

Clinical Importance

Knowledge of prostate anatomy is central to understanding cancer distribution, biopsy sampling, and treatment complications.


19. Prostate Zones

Peripheral Zone

Most prostate adenocarcinomas arise in this zone.

Transition Zone

A common location for benign prostatic hyperplasia.

Prostate cancer may also arise here.

Central Zone

Less frequently the primary site of prostate cancer.

Clinical Importance

The Peripheral Zone Is The Most Common Site Of Prostate Adenocarcinoma.


20. Pathophysiology of Prostate Adenocarcinoma

General Mechanism

Malignant transformation involves progressive molecular and cellular changes.

Important Processes

  • Genetic abnormalities.
  • Altered growth signaling.
  • Disruption of cell-cycle regulation.
  • Loss of normal glandular organization.
  • Invasive growth.
  • Potential metastatic spread.


21. High-Grade Prostatic Intraepithelial Neoplasia

HGPIN.

Definition

Atypical proliferation of prostatic glandular epithelial cells within pre-existing ducts and acini, with preservation of the basal cell layer.

Historical Subsequent Cancer Detection Risk

16–44%.

Historical Recommendation

Repeat biopsy within one year was not always necessary in the absence of other suspicious findings.

Contemporary Clinical Importance

Isolated Focal HGPIN On An Adequate Prostate Biopsy Does Not Automatically Require Immediate Repeat Biopsy.

Further assessment depends on:

  • PSA.
  • MRI.
  • Extent of HGPIN.
  • Previous sampling.
  • Other cancer risk factors.


22. Atypical Small Acinar Proliferation

ASAP.

Definition

Small atypical prostate glands suspicious for adenocarcinoma but insufficient for a definitive cancer diagnosis.

Historical Cancer Detection Risk on Subsequent Biopsy

42–49%.

Clinical Importance

ASAP requires additional evaluation because clinically significant cancer may have been missed.

Contemporary Approach

Consider:

  • Repeat PSA assessment.
  • Prostate MRI.
  • Targeted and systematic sampling.
  • Repeat biopsy when indicated.

Important Qualification

ASAP is not equivalent to a confirmed malignant diagnosis or a distinct obligatory premalignant lesion.


23. Histological Types of Prostate Cancer

Adenocarcinoma

The dominant histological type.

Frequency

More Than 95%.

Less Common Malignancies

  • Urothelial carcinoma involving the prostate.
  • Small-cell or neuroendocrine carcinoma.
  • Sarcoma.
  • Other rare malignant tumours.

Clinical Importance

Some aggressive nonadenocarcinoma variants may progress without substantial PSA elevation.


24. Histopathology of Adenocarcinoma

Main Microscopic Findings

  • Crowded, irregular glands.
  • Loss of normal glandular architecture.
  • Prominent nucleoli.
  • Nuclear enlargement.
  • Infiltrative growth.

Characteristic Diagnostic Finding

Absence of the basal cell layer.

Clinical Importance

Basal cell immunohistochemistry may help distinguish conventional adenocarcinoma from benign or atypical glands.


25. Gleason Grading

General Principle

The Gleason system grades prostate adenocarcinoma according to glandular architecture.

Historical Scale

Patterns 1–5.

Gleason Score

The primary and secondary histological patterns are combined.

Examples

  • Gleason 3 + 3 = 6.
  • Gleason 3 + 4 = 7.
  • Gleason 4 + 3 = 7.
  • Gleason 4 + 4 = 8.
  • Gleason 4 + 5 = 9.

Important Qualification

Gleason patterns 1 and 2 are not used in routine contemporary needle-biopsy grading.


26. ISUP Grade Groups

Grade Group 1

Gleason 3 + 3 = 6.

Grade Group 2

Gleason 3 + 4 = 7.

Grade Group 3

Gleason 4 + 3 = 7.

Grade Group 4

Gleason Score 8.

Grade Group 5

Gleason Scores 9–10.

Clinical Importance

Gleason 4 + 3 Is More Aggressive Than Gleason 3 + 4 Despite Both Having A Total Score Of Seven.


27. Cribriform and Intraductal Histology

Contemporary Significance

Cribriform carcinoma and intraductal carcinoma of the prostate are important adverse pathological findings.

Clinical Importance

Their presence may affect eligibility for active surveillance.

Contemporary European guidance recommends excluding patients with these histological patterns from routine active surveillance.


28. Clinical Presentation

General Principles

Early localized prostate cancer is frequently asymptomatic.

Common Detection Methods

  • PSA testing.
  • Digital rectal examination.
  • MRI.
  • Biopsy following risk assessment.

Clinical Importance

Most Localized Prostate Cancers Do Not Produce Specific Urinary Symptoms.


29. Local Urinary Symptoms

Occasional symptoms include:

  • Weak urinary stream.
  • Hesitancy.
  • Frequency.
  • Urgency.
  • Incomplete bladder emptying.
  • Urinary retention.

Important Qualification

These symptoms are often caused by benign prostatic hyperplasia rather than prostate cancer.


30. Other Local Symptoms

Possible presentations include:

  • Hematuria.
  • Hematospermia.
  • Erectile dysfunction.
  • Pelvic discomfort.

Clinical Importance

These findings are nonspecific and require appropriate differential diagnosis.


31. Metastatic Symptoms

Advanced disease may present with:

  • Bone pain.
  • Weight loss.
  • Fatigue.
  • Malaise.
  • Pathological fractures.
  • Neurological deficits.


32. Spinal Cord Compression

Mechanism

Metastatic tumour may compress the spinal cord or cauda equina.

Possible Manifestations

  • Severe back pain.
  • Limb weakness.
  • Sensory changes.
  • Urinary retention.
  • Bowel dysfunction.
  • Paralysis.

Clinical Importance

Suspected Metastatic Spinal Cord Compression Is An Oncological Emergency Requiring Urgent Assessment And Treatment.


33. Physical Examination

Digital Rectal Examination

DRE.

Suspicious Findings

  • Hard nodules.
  • Induration.
  • Asymmetry.
  • Irregular gland contour.

Clinical Importance

An abnormal DRE increases the suspicion of prostate cancer.

Important Limitation

A normal DRE does not exclude clinically significant cancer.


34. PSA Testing

Definition

Prostate-specific antigen is a protein secreted by prostatic epithelial cells.

Principal Uses

  • Prostate cancer risk assessment.
  • Treatment response monitoring.
  • Detection of biochemical recurrence.
  • Assessment of disease progression.

Important Principle

PSA Is Organ-Specific But Not Cancer-Specific.


35. Causes of Elevated PSA

Important causes include:

  • Prostate cancer.
  • Benign prostatic hyperplasia.
  • Prostatitis.
  • Urinary tract inflammation.
  • Recent urinary retention.
  • Some forms of prostatic manipulation.

Clinical Importance

An elevated PSA requires interpretation within the clinical context.


36. PSA Screening

Historical Source

The original chapter describes controversy regarding PSA screening because sensitivity and specificity are imperfect.

Main Potential Benefit

Earlier detection of clinically significant prostate cancer.

Main Potential Harms

  • False-positive results.
  • Unnecessary imaging.
  • Unnecessary biopsy.
  • Overdiagnosis.
  • Overtreatment.
  • Treatment-related urinary and sexual complications.


37. Contemporary Risk-Adapted Screening

Current European guidance supports offering informed PSA testing based on individual risk.

Typical Starting Ages

  • 50 years: Men at average risk.
  • 45 years: Men of African descent.
  • 45 years: Men with relevant early family history.
  • 40 years: Men carrying BRCA2 pathogenic variants.

Important Qualification

Screening decisions should also account for life expectancy and personal preferences.


38. Life Expectancy and Screening

Patients with limited life expectancy may be unlikely to benefit from detecting asymptomatic localized prostate cancer.

Contemporary Clinical Principle

Routine early-detection testing is generally discouraged in asymptomatic men whose life expectancy is below approximately 10–15 years.

Important Qualification

Symptomatic patients require appropriate clinical assessment regardless of screening eligibility.


39. PSA Velocity

Definition

The rate of PSA change over time.

Historical Adverse Threshold

Greater Than 2 ng/mL per Year.

The source associates this with poorer outcomes after treatment.

Important Contemporary Qualification

PSA velocity should not be used as the sole indication for prostate biopsy.


40. Percentage Free PSA

Definition

The proportion of PSA circulating in unbound form.

Clinical Interpretation

Lower Percentage Free PSA Is Associated With Greater Probability Of Prostate Cancer in selected patients with moderately elevated PSA.

Clinical Importance

Can contribute to risk assessment when the decision to biopsy remains uncertain.


41. PSA Density

Definition

PSA concentration divided by prostate volume.

Formula

PSA Density = Serum PSA / Prostate Volume.

Typical Units

ng/mL/cm³.

Clinical Importance

Higher PSA density increases suspicion for clinically significant prostate cancer.

A historical commonly used threshold is:

0.15 ng/mL/cm³.

Important Qualification

Interpretation depends on MRI findings and the complete risk profile.


42. Additional Laboratory Markers

Prostatic Acid Phosphatase

Historically used in prostate cancer evaluation.

Clinical Role

Limited in contemporary routine practice.

Alkaline Phosphatase

May be elevated in patients with osteoblastic bone metastases.

Important Qualification

An elevated alkaline phosphatase is not specific for metastatic prostate cancer.


43. Initial Diagnostic Approach

Modern Clinical Sequence

  1. Assess PSA and clinical risk factors.
  2. Repeat an unexpectedly elevated PSA when appropriate.
  3. Perform DRE.
  4. Consider validated risk calculators or adjunctive biomarkers.
  5. Obtain prebiopsy prostate MRI when indicated.
  6. Determine whether biopsy is necessary.
  7. Perform targeted or systematic sampling as appropriate.
  8. Establish pathological Grade Group.
  9. Complete stage-appropriate metastatic evaluation.


44. Multiparametric Prostate MRI

Clinical Role

Contemporary MRI helps:

  • Detect suspicious lesions.
  • Estimate lesion extent.
  • Identify clinically significant cancer.
  • Guide prostate biopsy.
  • Assist local staging.

Important Sequences

  • T2-weighted imaging.
  • Diffusion-weighted imaging.
  • Apparent diffusion coefficient maps.
  • Dynamic contrast-enhanced imaging when used.


45. PI-RADS

Definition

Prostate Imaging Reporting and Data System.

Interpretation

PI-RADS scores range from 1 to 5.

  • PI-RADS 1–2: Low suspicion.
  • PI-RADS 3: Equivocal.
  • PI-RADS 4: High suspicion.
  • PI-RADS 5: Very high suspicion.

Clinical Importance

MRI Findings Help Determine Whether Prostate Biopsy Is Appropriate And Where Samples Should Be Obtained.


46. Transrectal Ultrasound

TRUS.

Historical Role

Used principally to guide needle biopsy.

Classical Ultrasound Finding

Hypoechoic peripheral-zone nodule.

Important Qualification

Cancer may be:

  • Hypoechoic.
  • Isoechoic.
  • Hyperechoic.

TRUS alone cannot reliably exclude malignancy.


47. Prostate Biopsy

Historical Standard

10–12 Systematic Cores.

Important Sampling Regions

  • Base.
  • Mid-gland.
  • Apex.
  • Posterolateral peripheral zone.


48. MRI-Targeted Biopsy

Current Role

Sampling directed toward lesions identified on prostate MRI.

Main Methods

  • Cognitive targeting.
  • MRI–ultrasound fusion.
  • In-bore MRI-guided biopsy.

Contemporary Consideration

Targeted biopsy may be combined with perilesional or systematic sampling according to MRI and clinical risk.


49. Transperineal Biopsy

Definition

Needle biopsy performed through the perineal skin.

Main Advantage

Reduced exposure to rectal bacteria.

Clinical Importance

Transperineal Biopsy Is Preferred In Contemporary European Guidance Because Of Its Lower Infectious Risk.


50. Pathological Staging

TNM System

Prostate cancer is staged according to:

  • Primary tumour extent: T.
  • Regional lymph node involvement: N.
  • Distant metastatic spread: M.


51. T1 Disease

General Definition

Clinically inapparent tumour not palpable on examination.

T1a and T1b

Cancer identified incidentally in resected prostate tissue.

T1c

Cancer detected through needle biopsy, typically after an elevated PSA.

Historical Observation

The source reports approximately 75% of newly diagnosed prostate cancers as T1c in some screening-era populations.


52. T2 Disease

Definition

Tumour confined within the prostate.

Clinical Importance

Potentially suitable for curative local treatment or active surveillance depending on risk.


53. T3 Disease

T3a

Extraprostatic extension.

T3b

Seminal vesicle invasion.

Clinical Importance

Associated with greater risk of recurrence and progression.


54. T4 Disease

Definition

Tumour invades adjacent structures beyond the seminal vesicles.

Clinical Importance

Represents locally advanced disease.


55. Nodal and Metastatic Classification

N1

Regional lymph node involvement.

M1a

Nonregional lymph node metastases.

M1b

Bone metastases.

M1c

Metastasis to other sites, with or without bone involvement.


56. Patterns of Spread

Direct Extension

Prostate cancer can extend beyond the gland into nearby tissues.

Important Routes

  • Perineural spaces.
  • Lymphovascular channels.
  • Direct local invasion.

Regional Spread

Pelvic lymph nodes.

Distant Spread

Most commonly bone.

Other possible sites include:

  • Lung.
  • Liver.
  • Central nervous system in advanced disease.


57. Bone Metastases

Classical Pattern

Osteoblastic metastases.

Typical Sites

  • Spine.
  • Pelvis.
  • Ribs.
  • Other axial skeletal structures.

Clinical Consequences

  • Bone pain.
  • Pathological fracture.
  • Spinal cord compression.

Important Qualification

Prostate cancer metastases may also be mixed or predominantly lytic in selected cases.


58. Staging Investigations

Historical Approach

The source recommends:

  • CT abdomen and pelvis.
  • Bone scintigraphy.

Particularly for intermediate-risk and high-risk disease.

Historical Imaging Triggers

  • PSA greater than 10 ng/mL.
  • Gleason score 7 or greater.
  • Clinical stage T2b or higher.

Important Qualification

These thresholds are historical and should not be used as universal indications for current imaging.


59. PSMA PET/CT

Contemporary Role

Prostate-specific membrane antigen PET/CT provides sensitive evaluation of metastatic prostate cancer.

Important Applications

  • Pelvic lymph node assessment.
  • Distant lymph node staging.
  • Bone metastasis detection.
  • Restaging recurrent disease.

Clinical Importance

PSMA PET/CT Is A Preferred Staging Investigation For High-Risk Localized And Locally Advanced Prostate Cancer When Available.


60. Risk Stratification

Risk grouping combines:

  • PSA.
  • Grade Group.
  • Clinical T stage.
  • Extent of disease.


61. Historical Low-Risk Disease

The original source describes:

  • Clinical stage T1–T2a.
  • Gleason score 6 or lower.
  • PSA below 10 ng/mL.

Contemporary Interpretation

Generally corresponds to ISUP Grade Group 1 and favorable clinical features.


62. Historical Intermediate-Risk Disease

The source describes:

  • Clinical stage T2b–T2c.
  • Gleason score 7.
  • PSA 10–20 ng/mL.

Contemporary Qualification

Intermediate-risk disease is now separated into favorable and unfavorable groups.


63. Historical High-Risk Disease

The original source describes:

  • Stage T3a or greater.
  • Gleason score 8–10.
  • PSA greater than 20 ng/mL.

Important Qualification

Modern classifications more precisely distinguish high-risk localized from locally advanced disease.


64. Contemporary Risk Groups

Low Risk

Generally characterized by:

  • ISUP Grade Group 1.
  • PSA below 10 ng/mL.
  • Organ-confined clinical stage.

Favorable Intermediate Risk

May include:

  • ISUP Grade Group 2 with favorable PSA and clinical stage.
  • Selected Grade Group 1 disease with PSA 10–20 ng/mL.

Unfavorable Intermediate Risk

May include:

  • Grade Group 3.
  • Grade Group 2 with additional adverse features.

High Risk

May include:

  • Grade Group 4–5.
  • PSA greater than 20 ng/mL.

Locally Advanced

Includes:

  • cT3–T4 disease.
  • Regional nodal disease in the relevant clinical classification.

Clinical Importance

Risk Stratification Determines Whether Active Surveillance, Local Treatment, Combined-Modality Treatment, Or Systemic Therapy Is Most Appropriate.


65. Differential Diagnosis

Benign Prostatic Hyperplasia

Can cause:

  • Elevated PSA.
  • Urinary symptoms.
  • Enlarged prostate.

Prostatitis

May be:

  • Acute.
  • Chronic.
  • Granulomatous.

Clinical Importance

Inflammation may mimic malignancy through PSA elevation or abnormal MRI findings.

Recent Instrumentation

May be associated with temporary PSA changes in selected circumstances.

Other Prostate Malignancies

  • Urothelial carcinoma.
  • Sarcoma.
  • Neuroendocrine carcinoma.


66. Differential Diagnosis of Metastatic Findings

Bone Disease

  • Paget disease.
  • Other malignant bone lesions.
  • Other causes of abnormal bone imaging.

Lymphadenopathy

  • Lymphoma.
  • Tuberculosis.
  • Other infections.
  • Nonprostatic metastatic malignancy.


67. General Treatment Principles

Management is determined by:

  1. Cancer risk group.
  2. Clinical stage.
  3. Life expectancy.
  4. Overall health.
  5. Urinary function.
  6. Sexual function.
  7. Patient preference.

Main Treatment Categories

  • Active surveillance.
  • Watchful waiting.
  • Radical prostatectomy.
  • Radiotherapy.
  • Selected focal or ablative therapies.
  • Androgen-deprivation therapy.
  • Systemic therapy.


68. Active Surveillance

Definition

A structured monitoring strategy for prostate cancer with favorable biological characteristics.

Main Objective

Avoid unnecessary treatment while preserving the opportunity for curative treatment if clinically meaningful progression occurs.


69. Ideal Active Surveillance Candidates

The historical source describes:

  • PSA below 10 ng/mL.
  • Clinical stage T1c.
  • Gleason score 6 or lower.
  • Fewer than three positive biopsy cores.
  • Less than 50% cancer involvement in each core.
  • PSA density below 0.15 ng/mL/cm³.

Important Qualification

These represent historical highly selective inclusion criteria.

Modern MRI-informed active surveillance is broader in some circumstances.


70. Contemporary Active Surveillance

Standard Indication

Low-Risk Localized Prostate Cancer.

Selected Additional Indication

Carefully selected favorable intermediate-risk disease, including some Grade Group 2 tumours.

Important Requirements

  • Low cancer volume.
  • Favorable pathological features.
  • Appropriate MRI findings.
  • Ability to comply with surveillance.
  • Informed patient preference.


71. Active Surveillance Monitoring

Contemporary European guidance includes:

  • PSA at least every six months.
  • Clinical review.
  • MRI when indicated.
  • Repeat biopsy according to protocol and risk.

Important Principle

Changes In PSA Or MRI Should Prompt Reassessment, But Definitive Treatment Decisions Generally Require Confirmation Of Clinically Meaningful Disease Progression.


72. Watchful Waiting

Definition

A less intensive management strategy focused on symptom control rather than routine attempts to cure the cancer.

Main Candidates

Patients with:

  • Limited life expectancy.
  • Significant comorbidities.
  • Low likelihood of benefiting from curative treatment.

Clinical Importance

Watchful Waiting Is Not The Same As Active Surveillance.


73. Radical Prostatectomy

Definition

Surgical removal of:

  • Prostate gland.
  • Seminal vesicles.

Followed by reconstruction of urinary continuity between the bladder and urethra.

Main Goal

Curative treatment of appropriate localized or selected locally advanced disease.


74. Surgical Approaches

The historical source describes:

  • Open retropubic surgery.
  • Open perineal surgery.
  • Laparoscopic surgery.
  • Robot-assisted laparoscopic surgery.

Clinical Importance

Choice of technique depends on surgical expertise, anatomy, and clinical circumstances.


75. Robot-Assisted Radical Prostatectomy

Potential Benefits

  • Reduced blood loss.
  • Shorter hospitalization in some settings.
  • Enhanced visualization.
  • Minimally invasive access.

Important Qualification

Long-term oncological and functional outcomes depend heavily on surgeon experience and patient characteristics.

Robotic surgery does not guarantee superior cancer control.


76. Nerve-Sparing Surgery

Clinical Goal

Preserve erectile function by protecting relevant neurovascular structures.

Important Requirement

Nerve preservation must be oncologically appropriate.

Clinical Importance

Nerve-Sparing Radical Prostatectomy Should Be Considered When Cancer Extent Permits Safe Preservation Of Neurovascular Structures.


77. Pelvic Lymph Node Dissection

Clinical Role

Provides pathological nodal staging in selected patients.

Important Considerations

  • Recurrence risk.
  • Probability of nodal involvement.
  • Surgical morbidity.
  • Overall treatment plan.


78. Complications of Radical Prostatectomy

Important complications include:

  • Urinary incontinence.
  • Erectile dysfunction.
  • Bleeding.
  • Infection.
  • Anastomotic stricture.
  • Lymphocele following nodal dissection.
  • Other surgical complications.


79. Radiation Therapy

Main Modalities

  • External-beam radiotherapy.
  • Brachytherapy.

Clinical Objective

Deliver a tumouricidal radiation dose while limiting damage to surrounding tissues.


80. External-Beam Radiotherapy

Historical Techniques

The source emphasizes:

  • Intensity-modulated radiotherapy.
  • Image-guided radiotherapy.

Contemporary Techniques

  • IMRT.
  • VMAT.
  • IGRT.

Clinical Importance

Modern radiation planning allows improved dose conformity and sparing of adjacent normal structures.


81. Hypofractionated Radiotherapy

Definition

Radiation delivered using larger doses per fraction over fewer treatment sessions.

Historical Position

The source describes hypofractionation as being investigated in clinical trials.

Contemporary Qualification

Moderately Hypofractionated Radiotherapy Is An Established Standard Treatment Option For Appropriate Patients With Localized Prostate Cancer.

Selected patients may also receive stereotactic body radiotherapy.


82. Proton Beam Therapy

Clinical Principle

Uses proton particles to deliver radiation.

Historical Source

Describes increasing support for the technique.

Important Qualification

Proton therapy has not demonstrated consistent clinical superiority over high-quality modern photon radiotherapy for all prostate cancer patients.


83. Brachytherapy

Definition

Radiation delivered using radioactive sources placed within the prostate.

Two Main Types

  • Low-dose-rate brachytherapy.
  • High-dose-rate brachytherapy.


84. Low-Dose-Rate Brachytherapy

LDR.

Historical Radioisotopes

  • Iodine-125.
  • Palladium-103.

Method

Permanent radioactive seeds placed into the prostate.

Historical Selection

Low-risk disease with prostate volume below approximately 60 g.

Important Qualification

Prostate volume is one of several selection factors rather than an absolute universal threshold.


85. High-Dose-Rate Brachytherapy

HDR.

Historical Radioisotope

Iridium-192.

Method

Temporary catheters deliver a high radiation dose directly to the prostate.

Clinical Role

May be used alone or with external-beam radiotherapy in selected patients.


86. Radiotherapy Plus ADT

General Principle

Combining radiation with androgen suppression improves outcomes in selected intermediate-risk and high-risk patients.


87. Intermediate-Risk Radiotherapy

Typical ADT Duration

Approximately:

4–6 Months

when ADT is indicated.

Important Qualification

Selected favorable intermediate-risk patients may not require ADT.


88. High-Risk Radiotherapy

Typical ADT Duration

Approximately:

2–3 Years.

Clinical Importance

Long-Term ADT Combined With Definitive Radiotherapy Is A Standard Treatment Strategy For Appropriate High-Risk Localized Prostate Cancer.


89. Locally Advanced and Node-Positive Disease

Treatment often involves combined modalities.

Possible Components

  • Radiation to the prostate.
  • Pelvic nodal radiation.
  • Long-term ADT.
  • Selected treatment intensification.

Contemporary Consideration

Abiraterone plus corticosteroid may be added in eligible patients with specified high-risk nonmetastatic or node-positive disease.


90. Cryotherapy

Definition

Destruction of prostate tissue through freezing and thawing.

Historical Source

Describes placement of multiple cryoprobes under ultrasound guidance.

Clinical Importance

The freezing zone is monitored to limit damage to adjacent structures.

Contemporary Qualification

Whole-gland or focal cryotherapy is not considered routine standard primary treatment for all localized prostate cancers.

European guidance restricts its use to clinical trials or registries.


91. High-Intensity Focused Ultrasound

HIFU.

Definition

Focused ultrasound energy produces thermal tissue destruction.

Historical Source

Describes HIFU as investigational.

Contemporary Qualification

HIFU remains a selected ablative option with less mature long-term comparative evidence than established surgery or radiation.


92. Metastatic Prostate Cancer

General Principle

Most metastatic prostate adenocarcinomas initially remain sensitive to androgen suppression.

Clinical Category

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).


93. Androgen-Deprivation Therapy

ADT.

Main Goal

Reduce androgen signaling and suppress prostate cancer growth.

Main Methods

  • GnRH agonists.
  • GnRH antagonists.
  • Bilateral orchiectomy.


94. GnRH Agonists

Historical Examples

  • Leuprolide.
  • Goserelin.
  • Triptorelin.
  • Histrelin.

Mechanism

Continuous stimulation of pituitary GnRH receptors eventually suppresses:

  • LH.
  • FSH.

Consequence

Reduced testicular testosterone production.


95. Testosterone Flare

GnRH agonists initially increase testosterone before suppression occurs.

Potential Complications

  • Bone pain exacerbation.
  • Urinary obstruction.
  • Worsening metastatic symptoms.
  • Spinal cord compression in susceptible patients.

Historical Prevention

Oral antiandrogen treatment initiated before the first GnRH agonist dose.


96. GnRH Antagonists

Historical Example

Degarelix.

Contemporary Additional Example

Relugolix.

Mechanism

Direct blockade of pituitary GnRH receptors.

Main Advantage

Rapid testosterone suppression without initial agonist-related flare.


97. Bilateral Orchiectomy

Definition

Surgical removal of both testes.

Clinical Effect

Rapid and permanent reduction of testosterone production.

Advantages

  • No need for ongoing medical castration injections.
  • Rapid androgen suppression.

Limitations

  • Irreversible.
  • Sexual side effects.
  • Psychological implications.


98. Antiandrogens

Historical Examples

  • Flutamide.
  • Bicalutamide.
  • Nilutamide.

Mechanism

Block androgen receptor activity.

Historical Role

Often used alongside GnRH agonists.

Contemporary Qualification

First-generation antiandrogen monotherapy is generally not the preferred systemic treatment for metastatic disease.


99. Contemporary Treatment of mHSPC

Main Principle

ADT Alone Is Generally Insufficient For Fit Patients With Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Treatment intensification improves survival in appropriate patients.


100. ADT Plus Androgen Receptor Pathway Inhibitors

Important options include:

  • Abiraterone plus prednisone or prednisolone.
  • Enzalutamide.
  • Apalutamide.
  • Darolutamide in selected circumstances.

Clinical Importance

Combination Therapy Is A Standard Approach For Most Eligible Patients With Metastatic Hormone-Sensitive Prostate Cancer.


101. Docetaxel

Drug Class

Taxane chemotherapy.

Mechanism

Interferes with microtubule function.

Clinical Role

Used in selected metastatic prostate cancer settings.

Contemporary mHSPC Context

Docetaxel is commonly considered as part of intensified combination treatment in appropriately selected fit patients.


102. Triplet Therapy

Definition

Combination of:

  1. ADT.
  2. Docetaxel.
  3. An androgen receptor pathway inhibitor.

Important Examples

  • ADT + docetaxel + darolutamide.
  • ADT + docetaxel + abiraterone.

Clinical Importance

Triplet therapy may benefit selected patients, particularly those with substantial metastatic disease burden.


103. Prostate Radiation in Metastatic Disease

Selected patients with newly diagnosed low-volume metastatic disease may benefit from radiation to the prostate.

Clinical Importance

Treatment Of The Primary Prostate Tumour Can Improve Outcomes In Selected Patients With Low-Volume De Novo Metastatic Disease.


104. Castration-Resistant Prostate Cancer

CRPC.

Definition

Prostate cancer that progresses despite appropriately suppressed testosterone.

Historical Castration Threshold

Testosterone Below 50 ng/dL.

Clinical Progression

May involve:

  • Increasing PSA.
  • Radiological progression.
  • Clinical progression.


105. Nonmetastatic CRPC

Definition

Castration-resistant disease without detectable distant metastases on the specified imaging assessment.

Important Prognostic Factor

PSA doubling time.

Contemporary Treatment Options

Selected high-risk patients may receive:

  • Apalutamide.
  • Enzalutamide.
  • Darolutamide.

Generally while continuing ADT.


106. Metastatic CRPC

mCRPC.

General Principle

Disease progresses despite castrate testosterone and has evidence of metastatic spread.

Main Treatment Categories

  • Androgen receptor pathway inhibitors.
  • Taxane chemotherapy.
  • PARP inhibitors in molecularly selected patients.
  • Radioligand therapy.
  • Radium-223 in selected bone-metastatic disease.
  • Immunotherapy in selected circumstances.


107. Historical Ketoconazole Therapy

Historical Mechanism

Inhibition of adrenal and gonadal androgen synthesis.

Historical Use

Secondary hormonal manipulation.

Contemporary Qualification

Ketoconazole has largely been superseded by more selective and effective therapies, including abiraterone.


108. Abiraterone

Mechanism

Inhibits CYP17-dependent androgen synthesis.

Clinical Importance

Reduces androgen production from:

  • Adrenal glands.
  • Testicular sources.
  • Tumour-associated pathways.

Important Requirement

Administered with an appropriate corticosteroid regimen.


109. Enzalutamide

Drug Class

Androgen receptor signaling inhibitor.

Mechanism

Blocks multiple aspects of androgen receptor activity.

Clinical Role

Used in several advanced prostate cancer settings according to disease stage and prior treatment.


110. Docetaxel and Cabazitaxel

Docetaxel

A taxane used in metastatic prostate cancer.

Cabazitaxel

Another taxane, particularly relevant after selected previous therapies, including docetaxel.

Important Toxicities

  • Myelosuppression.
  • Neutropenia.
  • Infection.
  • Fatigue.
  • Neuropathy.


111. Sipuleucel-T

Definition

Autologous cellular immunotherapy.

Historical Source Indication

Asymptomatic or minimally symptomatic metastatic CRPC.

Contemporary Qualification

An option for appropriately selected patients where available, particularly in the United States.


112. Radium-223

Mechanism

A bone-targeting alpha-emitting radiopharmaceutical.

Clinical Role

Selected patients with symptomatic bone-metastatic CRPC without visceral metastases.

Important Qualification

Treatment requires careful assessment of marrow function, fracture risk, and appropriate bone protection.


113. PARP Inhibitors

Clinical Principle

Some prostate cancers have defects in homologous recombination DNA repair.

Important Genetic Associations

  • BRCA1.
  • BRCA2.
  • Other homologous recombination repair genes.

Important Drugs

  • Olaparib.
  • Other approved PARP inhibitor regimens.

Clinical Importance

Molecular Testing Can Identify Patients With Advanced Prostate Cancer Who May Benefit From PARP Inhibitor-Based Treatment.


114. Lutetium-177 PSMA Radioligand Therapy

Definition

A radioligand treatment directed toward PSMA-expressing prostate cancer cells.

Important Agent

177Lu-PSMA-617.

Clinical Role

Selected patients with PSMA-positive metastatic CRPC, depending on previous treatment and applicable approval criteria.


115. Supportive Management of Advanced Disease

Important components include:

  • Pain control.
  • Bone protection.
  • Management of urinary obstruction.
  • Prevention and treatment of fractures.
  • Management of spinal cord compression.
  • Nutritional support.
  • Functional rehabilitation.
  • Palliative care when appropriate.


116. Prostate Cancer Prevention Trials

Prostate Cancer Prevention Trial

PCPT.

Medication

Finasteride.

Historical Finding

Approximately 23–25% reduction in prostate cancer detection.

Historical Concern

An increased proportion of high-grade cancers was detected.

Important Qualification

Subsequent analyses suggest that detection-related effects contributed to the high-grade cancer signal.

Finasteride is not routinely prescribed solely for prostate cancer prevention.


117. REDUCE Trial

Medication

Dutasteride.

Historical Finding

Reduced prostate cancer detection.

Concern

Possible high-grade cancer signal and uncertainty regarding prevention of clinically meaningful mortality.

Clinical Importance

Five-Alpha-Reductase Inhibitors Are Not Routinely Recommended Solely For Primary Prostate Cancer Prevention.


118. SELECT Trial

Full Name

Selenium and Vitamin E Cancer Prevention Trial.

Supplements Studied

  • Vitamin E.
  • Selenium.

Historical Termination

The trial was stopped early because of lack of benefit.

Later Findings

Vitamin E supplementation was associated with increased prostate cancer risk.

Clinical Importance

Vitamin E And Selenium Supplements Should Not Be Recommended As Proven Methods Of Preventing Prostate Cancer.


119. Lifestyle and Prevention

The source suggests:

  • Reduced excessive saturated fat intake.
  • Increased dietary fiber.
  • Regular exercise.
  • Healthy eating patterns.

Important Qualification

These are reasonable general health measures, but no particular food, antioxidant, or supplement has been proven to prevent prostate cancer.


120. Prognosis

Main Prognostic Factors

  • PSA.
  • Grade Group.
  • Clinical stage.
  • Metastatic status.
  • Surgical margins.
  • Seminal vesicle invasion.
  • Extraprostatic extension.
  • Lymph node involvement.
  • Treatment response.


121. Adverse Prognostic Features

The historical source identifies:

  • PSA at least 10 ng/mL.
  • Gleason score 7 or higher.
  • Stage T3 or greater.
  • Positive surgical margins.
  • Seminal vesicle invasion.
  • Capsular penetration.
  • Lymph node metastases.

Important Qualification

These features carry differing degrees of risk and should be combined into validated risk models where appropriate.


122. Genomic Prognostic Markers

Contemporary tissue-based genomic assays may help estimate recurrence or progression risk in selected situations.

Important Qualification

These tools supplement rather than replace:

  • PSA.
  • Grade Group.
  • Stage.
  • MRI.
  • Other established prognostic factors.


123. Disease-Related Complications

Important complications include:

  • Bladder outlet obstruction.
  • Urinary retention.
  • Hematuria.
  • Bone pain.
  • Pathological fractures.
  • Spinal cord compression.
  • Ureteral obstruction.
  • Renal impairment.

Clinical Importance

Ureteral obstruction may result from locally advanced or metastatic disease.


124. Surgery-Related Complications

Urinary Incontinence

May occur following prostatectomy.

Erectile Dysfunction

May result from injury to neurovascular structures.

Other Complications

  • Bleeding.
  • Infection.
  • Anastomotic stricture.


125. Radiation-Related Complications

Possible complications include:

  • Dysuria.
  • Urinary frequency.
  • Urinary urgency.
  • Hematuria.
  • Radiation proctitis.
  • Rectal bleeding.
  • Erectile dysfunction.
  • Urethral stricture.


126. ADT-Related Complications

Important adverse effects include:

  • Hot flushes.
  • Loss of libido.
  • Erectile dysfunction.
  • Fatigue.
  • Reduced muscle mass.
  • Increased fat mass.
  • Osteoporosis.
  • Metabolic disturbances.
  • Cardiovascular risk considerations.


127. Chemotherapy-Related Complications

Important complications include:

  • Neutropenia.
  • Febrile neutropenia.
  • Sepsis.
  • Peripheral neuropathy.
  • Fatigue.
  • Gastrointestinal toxicity.


128. Follow-Up After Radical Prostatectomy

Historical Schedule

PSA:

Every 6–12 Months for Five Years, Then Annually.

Expected PSA

Usually undetectable.

Clinical Importance

An increasing PSA after surgery may indicate biochemical recurrence.


129. Follow-Up After Radiotherapy

PSA generally falls gradually.

Historical Favorable Prognostic Marker

The source describes a PSA nadir below:

0.5 ng/mL.

Important Qualification

A PSA nadir below 0.5 ng/mL is a favorable historical response marker rather than a mandatory definition of successful radiotherapy.


130. Biochemical Recurrence Definitions

After Radical Prostatectomy

Conventionally:

PSA ≥0.2 ng/mL with confirmation.

After Radiotherapy

PSA Nadir + 2 ng/mL.

Clinical Importance

The Definitions Of Biochemical Recurrence Differ After Prostatectomy And Radiotherapy.


131. Digital Rectal Examination During Follow-Up

The historical source recommends DRE every other year.

Contemporary Qualification

Follow-up examination should be individualized.

Routine DRE may have limited additional value when PSA remains stable and no concerning clinical findings are present.


132. Follow-Up Imaging

The source recommends imaging for:

  • New bone pain.
  • Rapid PSA rise.
  • Short PSA doubling time.

Contemporary Imaging Options

  • PSMA PET/CT.
  • Prostate or pelvic MRI.
  • CT.
  • Bone scan in selected circumstances.

Clinical Importance

Routine Imaging Is Usually Unnecessary In Asymptomatic Patients With Stable PSA When The Result Would Not Change Management.


133. Clinical and Surgical Pearls

Epidemiology

  • Prostate cancer is a common male malignancy.
  • Risk increases with age.
  • Family history is important.
  • A substantial proportion of patients have indolent disease.

Pathology

  • More Than 95% Are Adenocarcinomas.
  • Most arise in the peripheral zone.
  • Loss of the basal cell layer is an important histological feature.
  • Gleason grading and ISUP Grade Groups guide prognosis.

Screening

  • PSA is not cancer-specific.
  • Risk-adapted screening is preferred.
  • Family history and inherited pathogenic variants influence screening decisions.
  • PSA velocity alone should not determine biopsy.

Diagnosis

  • Prostate MRI Before Biopsy Is Recommended In Appropriate Patients.
  • MRI-targeted sampling improves diagnostic assessment.
  • Transperineal biopsy reduces infection risk.
  • Pathology establishes diagnosis and Grade Group.

Staging

  • Use the TNM system.
  • PSA, Grade Group, and stage determine risk.
  • Bone metastases are often osteoblastic.
  • PSMA PET/CT improves metastatic staging.

Localized Disease

  • Active surveillance is standard for suitable low-risk disease.
  • Selected favorable intermediate-risk patients may also undergo surveillance.
  • Radical prostatectomy and radiotherapy are established curative treatments.
  • Treatment selection must consider urinary and sexual outcomes.

Advanced Disease

  • ADT remains foundational.
  • Fit patients with metastatic hormone-sensitive cancer usually benefit from combination therapy.
  • mCRPC requires stage- and treatment-specific systemic therapy.
  • Molecular testing may identify candidates for targeted treatment.


134. Essential Examination and Clinical Principles

1. Know the Most Common Histology

Prostatic adenocarcinoma.

2. Know the Most Common Anatomical Site

Peripheral zone.

3. Recognize the Importance of Family History

Especially early-onset prostate cancer or associated hereditary cancers.

4. Understand PSA Limitations

Elevated PSA is not specific for cancer.

5. Use MRI to Guide Biopsy Decisions

Prebiopsy MRI is a key contemporary diagnostic investigation.

6. Prefer Appropriate Transperineal Sampling

The principal advantage is lower infectious risk.

7. Know the ISUP Grade Groups

Gleason 3 + 4 differs prognostically from 4 + 3.

8. Recognize High-Risk Histology

Cribriform or intraductal carcinoma may preclude active surveillance.

9. Use Appropriate Staging

PSMA PET/CT is valuable in high-risk and locally advanced disease.

10. Offer Active Surveillance for Suitable Low-Risk Cancer

Avoid unnecessary treatment in patients with favorable disease.

11. Distinguish Active Surveillance From Watchful Waiting

The former preserves curative intent; the latter emphasizes symptom control.

12. Know the Main Curative Treatments

Radical prostatectomy and radiotherapy.

13. Combine Radiotherapy With ADT When Indicated

Short-term ADT for selected intermediate-risk disease and long-term ADT for high-risk disease.

14. Intensify Treatment for Most Fit Patients With Metastatic Hormone-Sensitive Disease

ADT alone is generally inadequate.

15. Recognize Castration Resistance

Progression despite castrate testosterone.

16. Understand Targeted Therapy

BRCA and other DNA repair abnormalities may influence use of PARP inhibitors.

17. Identify Spinal Cord Compression Immediately

This is an oncological emergency.

18. Maintain Long-Term PSA Surveillance

Recurrence may occur years after treatment.


135. Historical Clinical Context and Important Qualifications

Historical Incidence and Mortality

The source reports United States statistics from 2014.

These should not be presented as current epidemiological estimates.

Racial and Geographic Differences

The original figures reflect historical populations and screening practices.

Individual clinical risk should be assessed without assuming that population ancestry alone determines disease behavior.

Genetic Susceptibility

Several genes listed in the source are historical candidate genes.

Contemporary hereditary assessment places greater clinical emphasis on validated cancer-predisposition genes and molecular treatment implications.

Vitamin D

The source suggests vitamin D may be protective.

This has not been established as a reliable prostate cancer prevention strategy.

HGPIN and ASAP

Historical repeat-biopsy risk estimates should be interpreted using modern MRI-based diagnostic pathways.

PSA Velocity

The historical threshold of 2 ng/mL/year should not be used as the sole reason for biopsy.

Prostate MRI

The source describes MRI as an emerging investigation.

Prebiopsy MRI is now a major component of contemporary diagnosis.

Biopsy Technique

The historical source describes systematic TRUS biopsy as standard.

Transperineal MRI-directed approaches are now preferred in European guidance.

Localized Risk Classification

The original three-tier NCCN risk grouping has evolved.

Contemporary assessment separates favorable and unfavorable intermediate-risk disease and more precisely incorporates Grade Group and stage.

Hypofractionation

The source describes it as investigational.

Moderate hypofractionation is now established.

Cryotherapy and HIFU

The original chapter describes these as local treatment options.

Routine use remains limited by the quality and maturity of long-term comparative evidence.

Metastatic Treatment

The historical chapter emphasizes ADT alone.

Current management generally uses treatment intensification for fit patients with metastatic hormone-sensitive disease.

Castration-Resistant Disease

The original systemic therapy list predates newer molecularly targeted combinations and PSMA-directed radioligand treatment.

Vitamin E and Selenium

The SELECT trial did not show preventive benefit, and vitamin E supplementation was associated with increased prostate cancer risk.


136. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

601.9

Prostatitis, unspecified.

V16.42

Family history of malignant neoplasm of prostate.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

N41.9

Inflammatory disease of prostate, unspecified.

Z80.42

Family history of malignant neoplasm of prostate.

Coding Qualification

These codes are retained from the historical source. Clinical coding should reflect the confirmed diagnosis and currently applicable coding classification.


Final Urological Revision Summary

Prostate cancer is a biologically heterogeneous malignancy that most commonly arises as adenocarcinoma within the peripheral zone of the prostate.

Main Risk Factors

  • Increasing age.
  • Family history.
  • Inherited cancer-predisposition variants.
  • Population-associated risk factors.
  • Other genetic and environmental influences.

Important Diagnostic Investigations

  1. PSA.
  2. Digital rectal examination.
  3. Risk assessment.
  4. Prostate MRI.
  5. Targeted and/or systematic prostate biopsy.
  6. ISUP grading.
  7. TNM staging.
  8. PSMA PET/CT when indicated.

Main Localized Treatment Options

  • Active surveillance.
  • Watchful waiting.
  • Radical prostatectomy.
  • External-beam radiotherapy.
  • Brachytherapy.
  • Selected focal treatments within appropriate specialist frameworks.

Main Advanced-Disease Treatments

  • Androgen-deprivation therapy.
  • Androgen receptor pathway inhibitors.
  • Docetaxel.
  • Selected triplet therapy.
  • Cabazitaxel.
  • PARP inhibitors.
  • Radium-223.
  • Lutetium-177 PSMA therapy.
  • Immunotherapy in selected patients.

Main Prognostic Factors

  • PSA.
  • Grade Group.
  • Clinical stage.
  • Metastatic disease burden.
  • Surgical pathological features.
  • PSA response and kinetics.
  • Molecular characteristics in selected patients.

Main Complications

Disease-related

  • Bladder outlet obstruction.
  • Ureteral obstruction.
  • Bone pain.
  • Fractures.
  • Spinal cord compression.

Treatment-related

  • Urinary incontinence.
  • Erectile dysfunction.
  • Rectal toxicity.
  • Osteoporosis.
  • Metabolic complications.
  • Cardiovascular concerns.
  • Chemotherapy-related neutropenia and sepsis.

Main Follow-Up Priorities

  • Serial PSA.
  • Clinical symptoms.
  • Urinary function.
  • Sexual function.
  • Metastatic progression assessment when indicated.
  • ADT toxicity monitoring.
  • Bone and metabolic health.

The Central Urological Objective Is To Detect Clinically Significant Prostate Cancer Accurately, Avoid Overtreatment Of Indolent Disease, Select Curative Treatment According To Risk And Life Expectancy, Apply Appropriate Systemic Treatment For Advanced Disease, And Preserve Urinary, Sexual, Skeletal, And Overall Health Through Long-Term Follow-Up.

This chapter has been comprehensively paraphrased, including the original epidemiology, risk factors, historical genetics, pathology, screening, diagnosis, staging, localized and advanced treatments, prognosis, complications, and clinical pearls. Historical values and treatments are distinguished from contemporary recommendations. Author names, references, and additional reading have been omitted. No tables have been used.

 

Image description
0 Comments